These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 20815453)

  • 1. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model.
    Dille MF; McMillan GP; Reavis KM; Jacobs P; Fausti SA; Konrad-Martin D
    J Acoust Soc Am; 2010 Sep; 128(3):1163-74. PubMed ID: 20815453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
    Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
    Biró K
    Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
    Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
    Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
    Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
    Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distortion-product otoacoustic emission test performance for ototoxicity monitoring.
    Reavis KM; McMillan G; Austin D; Gallun F; Fausti SA; Gordon JS; Helt WJ; Konrad-Martin D
    Ear Hear; 2011 Feb; 32(1):61-74. PubMed ID: 20625302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
    Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
    J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Otoacoustic emissions measurements in children during the chemotherapy because of the acute lymphoblastic leukemia].
    Lisowska G; Namysłowski G; Hajduk A; Polok A; Tomaszewska R; Misiołek M
    Otolaryngol Pol; 2006; 60(3):415-20. PubMed ID: 16989457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
    Knight KR; Kraemer DF; Winter C; Neuwelt EA
    J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.
    Dhooge I; Dhooge C; Geukens S; De Clerck B; De Vel E; Vinck BM
    Int J Audiol; 2006 Jun; 45(6):337-43. PubMed ID: 16777780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of distortion-product otoacoustic emissions-based ototoxicity monitoring using various primary frequency step-sizes.
    McMillan GP; Konrad-Martin D; Dille MF
    Int J Audiol; 2012 Sep; 51(9):689-96. PubMed ID: 22676700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
    Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
    Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of high-dose cisplatin on auditory brainstem responses and otoacoustic emissions in laboratory animals.
    Sockalingam R; Freeman S; Cherny TL; Sohmer H
    Am J Otol; 2000 Jul; 21(4):521-7. PubMed ID: 10912698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of inner ear hearing loss on delayed otoacoustic emissions (TEOAE) and distortion products (DPOAE)].
    Hoth S
    Laryngorhinootologie; 1996 Dec; 75(12):709-18. PubMed ID: 9081275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of aspirin on distortion product fine structure: interpreted by the two-source model for distortion product otoacoustic emissions generation.
    Rao A; Long GR
    J Acoust Soc Am; 2011 Feb; 129(2):792-800. PubMed ID: 21361438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin ototoxicity in the Sprague Dawley rat evaluated by distortion product otoacoustic emissions.
    Hatzopoulos S; Di Stefano M; Campbell KC; Falgione D; Ricci D; Rosignoli M; Finesso M; Albertin A; Previati M; Capitani S; Martini A
    Audiology; 2001; 40(5):253-64. PubMed ID: 11688544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of hearing loss using 2f2-f1 and 2f1-f2 distortion-product otoacoustic emissions.
    Fitzgerald TS; Prieve BA
    J Speech Lang Hear Res; 2005 Oct; 48(5):1165-86. PubMed ID: 16411804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a cisplatin dose-ototoxicity model.
    Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
    J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeatability of high-frequency distortion-product otoacoustic emissions in normal-hearing adults.
    Dreisbach LE; Long KM; Lees SE
    Ear Hear; 2006 Oct; 27(5):466-79. PubMed ID: 16957498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.
    Konrad-Martin D; James KE; Gordon JS; Reavis KM; Phillips DS; Bratt GW; Fausti SA
    J Am Acad Audiol; 2010 May; 21(5):301-14; quiz 357. PubMed ID: 20569665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.